Free Trial
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
$1.15
$1.16
$0.81
▼
$1.65
$14.18M0.8511,089 shs431 shs
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$2.71
+3.0%		$4.40
$2.42
▼
$29.98
$27.22M0.3178,814 shs79,407 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
0.00%0.00%0.00%0.00%+25.00%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
0.00%-7.82%-46.86%-55.65%-86.20%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
$1.15
$1.16
$0.81
▼
$1.65
$14.18M0.8511,089 shs431 shs
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$2.71
+3.0%		$4.40
$2.42
▼
$29.98
$27.22M0.3178,814 shs79,407 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
0.00%0.00%0.00%0.00%+25.00%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
0.00%-7.82%-46.86%-55.65%-86.20%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
0.00
N/AN/AN/A
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
2.25
Hold$17.00527.31% Upside

Current Analyst Ratings Breakdown

Latest MCRB and HOOK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/18/2026
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
9/3/2026
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/11/2026
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 10/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
$9.35M1.52N/AN/A$4.25 per share0.27
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$790K34.48$1.09 per share2.49$4.89 per share0.55
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
-$43.50M-$3.54N/AN/AN/A-785.66%-120.09%-77.14%N/A
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$5.70M-$2.43N/AN/AN/A-1,192.94%-114.82%-34.15%11/4/2026 (Estimated)

Latest MCRB and HOOK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
-$1.0050N/AN/AN/A$6.35 millionN/A
8/5/2026Q2 2026
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
-$2.18$0.47+$2.65$0.47$0.18 million$0.74 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
N/AN/AN/AN/AN/A
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
N/A
3.61
3.61
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
N/A
2.11
2.11

Institutional Ownership

CompanyInstitutional Ownership
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
63.88%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
59.34%

Insider Ownership

CompanyInsider Ownership
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
3.30%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
5.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
16012.33 million11.79 millionOptionable
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
6610.05 million9.52 millionOptionable

Recent News About These Companies

Analysts see USD 17 target for Seres Therapeutics stock
October 8 at 8:34 PM  |  ad-hoc-news.deA
Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below Fifty Day Moving Average - Here's Why
October 8 at 4:01 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31098706
Seres Therapeutics (NASDAQ:MCRB) Share Price Crosses Below Fifty Day Moving Average - Time to Sell?
September 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31067429
Seres Therapeutics, Inc.(NasdaqGS:MCRB) dropped from S&P Global BMI Index
September 20, 2026  |  marketscreener.comM
Seres Therapeutics (NASDAQ:MCRB) and Celldex Therapeutics (NASDAQ:CLDX) Head to Head Review
September 16, 2026  |  defenseworld.netD
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3358236/0/en/seres-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
September 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3353940/0/en/seres-therapeutics-to-participate-in-h-c-wainwright-28th-annual-global-investment-conference.html
Canaccord Genuity Reaffirms Their Buy Rating on Seres Therapeutics (MCRB)
August 20, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MCRB/pressreleases/3715810/canaccord-genuity-reaffirms-their-buy-rating-on-seres-therapeutics-mcrb/
Seres Therapeutics: Q2 Earnings Snapshot
August 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/seres-therapeutics-q2-earnings-snapshot-111242137.html
Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs
August 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/seres-therapeutics-reports-second-quarter-110000129.html
Seres Therapeutics Streamlines Cambridge Operations with Lease Changes
August 4, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/seres-therapeutics-streamlines-cambridge-operations-with-lease-changes?utm_source=marketbeat.com&utm_medium=referral
Seres Therapeutics' SER-155 posts 80% response in cancer immunotherapy GI toxicity study
July 11, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/seres-therapeutics-ser-155-posts-80-response-in-cancer-immunotherapy-gi-toxicity-study/ar-AA27EwCK
Why Seres Therapeutics, Inc.’s (MCRB) Stock Is Down 11.18%
July 8, 2026  |  aaii.comA
Seres Therapeutics Shareholders Approve Directors and Executive Pay
July 8, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/seres-therapeutics-shareholders-approve-directors-and-executive-pay?utm_source=marketbeat.com&utm_medium=referral
Seres Therapeutics, Inc. (MCRB) Discusses Promising SER-155 Clinical Trial Results for Immune Checkpoint Inhibitor Related Andropilatis Transcript
July 8, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4920616-seres-therapeutics-inc-mcrb-discusses-promising-serminus-155-clinical-trial-results-for
Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That ...
July 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/seres-therapeutics-announces-early-clinical-110000466.html
Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment
July 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/08/3323958/0/en/seres-therapeutics-announces-early-clinical-data-showing-potential-for-ser-155-in-immune-checkpoint-inhibitor-related-enterocolitis-irec-a-frequent-adverse-reaction-that-forces-man.html
Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of ...
June 25, 2026  |  caledonianrecord.comC
Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis
June 25, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/seres-therapeutics-host-webcast-july-110000164.html
Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres' SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis
June 25, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/25/3317409/0/en/seres-therapeutics-to-host-webcast-on-july-8-2026-to-discuss-results-of-investigator-sponsored-trial-of-seres-ser-155-in-immune-checkpoint-inhibitor-related-enterocolitis.html

Media Sentiment Over Time

HOOKIPA Pharma stock logo

HOOKIPA Pharma NASDAQ:HOOK

HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

Seres Therapeutics stock logo

Seres Therapeutics NASDAQ:MCRB

$2.71 +0.08 (+3.04%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$2.76 +0.04 (+1.66%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas